Delivery Order SPE2DB22D3501-SPE2DB25FXB67
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Lynparza 150 mg tablets (120 count units) with a ceiling value of $42,270.40. This is a firm fixed-price delivery order with no set-aside designation, executed under competitive procurement procedures. The order is scheduled for ultimate completion by September 15, 2025, and will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania. As a child...
- The Defense Logistics Agency awarded a delivery order valued at $10,499.34 to AmerisourceBergen Drug Corp for 60 tablets of LYNPARZA 150 mg, a pharmaceutical product for oncology treatment. The contract, awarded on August 19, 2025, with an ultimate completion date of September 10, 2025, carries firm fixed pricing and represents a non-set-aside competitive award. Performance will be executed at the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Lynparza 150 mg tablets (120-count units) with a firm fixed price ceiling value of $21,135.20 and ultimate completion date of September 10, 2025. This delivery order represents a non-competitive award and is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00...
- The Defense Logistics Agency awarded a $42,270.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Lynparza 150 mg tablets (120-count units) on August 12, 2025, with an ultimate completion date of September 3, 2025. This non-competitive delivery order is being fulfilled from AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $5,249.67 to supply Lynparza 150 mg tablets (60-count units) under a firm fixed-price contract. The delivery order, issued on August 1, 2025, with an ultimate completion date of August 22, 2025, represents a non-set-aside, competitively awarded procurement. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen Drug Corp's corporate headquarters and primary...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Lynparza 150 mg tablets (120 count) valued at $31,702.80. This firm fixed-price delivery order is scheduled for completion by August 25, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $10,519.62 to AmerisourceBergen Drug Corp for 120 tablets of Lynparza 100 mg on August 20, 2025, with an ultimate completion date of September 11, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child order, this delivery falls under a larger contract...
- The Defense Logistics Agency awarded a $10,499.34 firm fixed price delivery order to AmerisourceBergen Drug Corp for 60 tablets of LYNPARZA 150 mg, with a completion date of August 25, 2025. This non-set-aside competitive award leverages AmerisourceBergen's position as a critical pharmaceutical distributor within the federal medical supply chain. The order will be fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of LYNPARZA 100 mg tablets (120-count units) with a ceiling value of $10,519.62. This firm fixed-price delivery order, with an ultimate completion date of September 9, 2025, represents a non-set-aside competitive award and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. LYNPARZA is an oncology pharmaceutical used in cancer treatment,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,519.62 for 120 tablets of Lynparza 100 mg on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside transaction executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be performed...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXB67Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of LYNPARZA 150 mg tablets (60-count unit dose) with a ceiling value of $10,499.34. This is a firm fixed-price delivery order with no set-aside designation, executed under competitive procedures. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 19, 2025. This delivery order is issued against AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The parent IDC vehicle enables the company to supply a comprehensive range of pharmaceutical products, medical devices, vaccines, and specialized healthcare commodities across multiple therapeutic domains to support defense healthcare needs globally. The company's delivery orders under this vehicle demonstrate consistent capability to fulfill federal medical supply requirements through open competition, with pricing ranging across various transaction sizes. This particular award for LYNPARZA, an oncology medication, reflects AmerisourceBergen's role in providing specialized pharmaceutical support to the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.5k | 8/28/25 |